Effectiveness outcomes in 443 adults with JIA starting first TNFi, by disease pattern category
| All (N=443) | Polyarticular (N=327) | Oligoarticular (N=7) | Systemic (N=12) | Enthesitis-related (N=53) | Psoriatic (N=44) | |
|---|---|---|---|---|---|---|
| DAS28 | ||||||
| Baseline | 6.2 (5.5–7.0) N=405 | 6.3 (5.6–7.0) N=322 | 3.9 (3.2–5.1) N=7 | 6.3 (5.8–7.1) N=12 | 5.9 (4.1–6.7) N=23 | 6.3 (5.5–6.9) N=41 |
| 1 year | 3.8 (2.6–5.0) N=309 | 3.9 (2.8–5.0) N=252 | 3.4 (2.7–3.4) N=4 | 5.1 (4.2–5.8) N=7 | 2.2 (1.7–4.4) N=17 | 3.4 (2.4–4.3) N=29 |
| Change in DAS28 at 1 year | −2.4 (−3.4 to −1.3)* N=297 | −2.4 (−3.4 to −1.3)* N=248 | −1.1 (−2.6 to −0.2) N=4 | −1.6 (−3.4 to −1.1)* N=7 | −2.3 (−3.8 to −1.7)* N=10 | −2.8 (−3.5 to −1.6)* N=28 |
| EULAR response (%) at 1 year | N=297 | N=248 | N=4 | N=7 | N=10 | N=28 |
| No response | 53 (18) | 46 (19) | 2 (50) | 1 (14) | 1 (10) | 3 (11) |
| Moderate | 147 (49) | 125 (50) | 1 (25) | 5 (71) | 4 (40) | 12 (43) |
| Good | 97 (33) | 77 (31) | 1 (25) | 1 (14) | 5 (50) | 13 (46) |
| DAS28 remission (%) at 1 year | 83 (27) N=309 | 59 (23) N=252 | 1 (25) N=4 | 1 (14) N=7 | 11 (65) N=17 | 11 (38) N=29 |
| HAQ | ||||||
| Baseline | 1.9 (1.5–3.4) N=403 | 2.0 (1.6–2.4) N=314 | 1.9 (1.0–2.3) N=6 | 2.1 (1.9–2.6) N=11 | 1.7 (0.8–2.0) N=32 | 1.9 (1.4–2.3) N=40 |
| 1 year | 1.5 (1.9–2.1) N=260 | 1.6 (1.0–2.1) N=200 | 1.4 (0.4–1.5) N=3 | 2.1 (1.6–2.3) N=5 | 1.0 (0.1–1.4) N=24 | 1.6 (1.1–1.9) N=28 |
| Change in HAQ at 1 year | −0.4 (−0.8 to 0.0)* N=242 | −0.4 (−0.8 to 0.0)* N=196 | −0.6 (−0.8 to −0.5)* N=3 | −0.3 (−0.4 to −0.1) N=5 | −0.5 (−0.8 to −0.1)* N=14 | −0.5 (0.8 to −0.1)* N=24 |
| HAQ MCID (%) at 1 year | 159 (66) N=242 | 126 (64) N=196 | 3 (100) N=3 | 3 (60) N=5 | 10 (71) N=14 | 17 (71) N=24 |
Presenting median (IQR), including number with available data (N) where applicable.
DAS28, 28-joint Disease Activity Score; EULAR, European League Against Rheumatism; HAQ, Health Assessment Questionnaire; JIA, juvenile idiopathic arthritis; MCID, minimal clinical important difference; TNFi, tumour necrosis factor inhibitor.
*p<0.05.